

TABLE 2. Correlation of clinical and laboratory parameters with PCSK9 in the population.

Variable	TIA patients		Control group	
	r	P-value	r	P-value
Age, years	0.634	0.003	-0.380	0.099
Male sex	-0.057	0.810	-0.075	0.752
BMI, kg/m ²	0.562	0.438	-0.259	0.271
Smoking	-0.216	0.360	0.060	0.800
Hx of hypertension	0.033	0.890	-0.036	0.881
Hx of dyslipidemia	0.393	0.086	0.493	0.027
Hx of diabetes mellitus	0.515	0.020		
Hx of CAD			N/A	N/A
Hx of PAD	N/A	N/A	N/A	N/A
Systolic BP	-0.196	0.408	0.191	0.419
Diastolic BP	-0.416	0.068	0.158	0.505
TC, mg/dL	0.066	0.781	0.188	0.427
TG, mg/dL	0.061	0.797	0.003	0.991
HDL-C, mg/dL	0.387	0.092	0.474	0.035
LDL-C, mg/dL	-0.107	0.653	0.142	0.550
ApoA1, mg/dL	0.299	0.200	0.322	0.166
ApoB, mg/dL	-0.291	0.213	0.184	0.437
Lp (a), mg/dL	-0.325	0.162	0.091	0.703
ABCD2	0.512	0.021	N/A	N/A
mRS	-0.116	0.625	N/A	N/A
NIHSS	-0.016	0.947	N/A	N/A

Abbreviations: Hx: history; N/A: non-applicable; BMI: body mass index; CAD: coronary artery disease; PAD: peripheral arterial disease; BP: blood pressure; The ABCD2 score is based on five parameters (age, blood pressure, clinical features, duration of TIA, and presence of diabetes); mRS: modified Rankin scale; NIHSS: National Institutes of Health Stroke Scale; TC: total cholesterol; LDL-C: low-density lipoprotein cholesterol; TG: triglycerides; HDL-C: high-density lipoprotein cholesterol; Apo: apolipoprotein; Lp: lipoprotein; PCSK9: proprotein convertase subtilisin/kexin type 9.

Conversions: To convert total cholesterol, LDL-C or HDL-C from [mg/dl] to [mmol/L] multiply by 0.02586; to convert TG from [mg/dL] to [mmol/L] multiply by 0.0113;